Listen to our next show with Dr. Sergio Giralt of the Memorial Sloan-Kettering Cancer Center to hear about his deep expertise in transplantation and his latest trials including the use of a vaccine in combination with transplant and a gene-targeted approach using cabozantinib.

Listen to Dr. Craig Crews of the Crews Laboratory at Yale University describe how a drug begins as an idea and becomes a real myeloma therapy used in the clinic. He shares his story of the discovery and development of the drug carfilzomib (Kyprolis).

This week on HealthTree Podcast for Multiple Myeloma we welcome Dr. James Berenson of the Institute for Myeloma & Bone Cancer Research (IMBCR) to discuss the latest in his research and his open clinical trials.

This week on HealthTree Podcast for Multiple Myeloma, we welcome Dr. William Bensinger of the Fred Hutchinson Cancer Research Center to discuss his research and many trials including a Kyprolis trial. With the recent announcement of Amgen's purchase of Onyx, we will be asking how we can continue to fast-track drug development for multiple myeloma.

This week on HealthTree Podcast for Multiple Myeloma we welcome Dr. Don Benson of The James Comprehensive Cancer Center at Ohio State University back to discuss his research in nk cells, immunotherapy, and an upcoming PD-1 trial.

This week on HealthTree Podcast for Multiple Myeloma, listen to Dr. Robert A. Kyle, a pioneer in myeloma research, as he gives us perspective on the history of "Innovation in Myeloma" and his lengthy research as the first to identify MGUS and smoldering myeloma.

This week on HealthTree Podcast for Multiple Myeloma, listen to Dr. Landgren as we discuss his research in new therapies for myeloma in its precursor states (MGUS and smoldering), molecular profiling of myeloma and why it is important in predicting progression, and his related research with myeloma and the immune system.

This week on HealthTree Podcast for Multiple Myeloma, listen to the first in a two-part series with Dr. Benson as he gives us a primer in clinical trials. Because only 5% of myeloma patients participate in clinical trials, we want you to know all about them so you can understand why you would want to enroll, how they are staged, who funds them and what you can expect in outcomes.

This week on HealthTree Podcast for Multiple Myeloma listen to Dr. Guido Tricot discuss his latest research and open clinical trials.

This week on HealthTree Podcast for Multiple Myeloma, listen to myeloma pioneer Dr. Robert Z. Orlowski discuss his latest research and open clinical trials in our first patient internet radio interview.